Cidara's Q3 Loss Widens on Soaring R&D, Cash Reserves Boosted by Offering

Cidara Therapeutics, Inc. 10-Q Filing Summary
FieldDetail
CompanyCidara Therapeutics, Inc.
Form Type10-Q
Filed DateNov 6, 2025
Risk Levelhigh
Pages16
Reading Time19 min
Key Dollar Amounts$0.0001
Sentimentmixed

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Clinical Trials, R&D Spending, Cash Burn, Public Offering, Antivirals

Related Tickers: CDTX

TL;DR

**Cidara's burning cash fast on CD388, but a massive capital raise gives them a fighting chance for a Phase 3 win.**

AI Summary

Cidara Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $132.4 million, up from $117.5 million in the prior year. This was primarily driven by a substantial increase in acquired in-process research and development (IPR&D) expenses, which surged to $45.0 million in Q3 2025 from zero in Q3 2024, and $45.0 million for the nine months ended September 30, 2025, compared to $84.9 million in the same period of 2024. Research and development expenses also rose sharply to $84.9 million for the nine months ended September 30, 2025, from $25.0 million in 2024. The company's cash and cash equivalents significantly increased to $293.7 million as of September 30, 2025, from $189.8 million at December 31, 2024, bolstered by $376.9 million from an underwritten public offering. Total assets grew to $518.7 million from $214.8 million. A key business change was the reacquisition of all rights for CD388 from Janssen on April 23, 2024, and the subsequent initiation of a global Phase 3 trial (ANCHOR study) for CD388 in September 2025. The company also sold its rezafungin assets to Napp Pharmaceutical Group Limited on April 24, 2024, classifying it as discontinued operations. The accumulated deficit expanded to $743.7 million by September 30, 2025, indicating continued unprofitability.

Why It Matters

Cidara's substantial increase in cash and cash equivalents to $293.7 million, primarily from a $376.9 million public offering, provides crucial runway for its ambitious CD388 development. The reacquisition of CD388 rights from Janssen and the rapid progression to a Phase 3 trial signals a focused strategic shift, but also concentrates risk on this single asset. For investors, the widening net loss to $132.4 million and accumulated deficit of $743.7 million highlight the significant capital burn inherent in late-stage biotech development. Competitors in the antiviral space will be watching the ANCHOR study closely, as a successful outcome for CD388 could disrupt the influenza prophylaxis market, impacting existing vaccine and treatment providers.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $743.7 million as of September 30, 2025, and expects to continue incurring net losses, indicating significant financial risk. The substantial increase in R&D expenses, including $45.0 million for acquired IPR&D in Q3 2025, reflects a high-cost, high-risk development strategy focused on a single lead candidate, CD388, which is now in Phase 3 trials. The success of CD388 is critical, and failure would severely impact the company's viability.

Analyst Insight

Investors should closely monitor the progress and clinical trial results of CD388, as its success is paramount to Cidara's future. Given the high burn rate and accumulated deficit, new investors should approach with caution, recognizing the significant risk-reward profile of a clinical-stage biotech. Existing investors should evaluate their position based on their conviction in CD388's potential and the company's ability to manage its cash runway effectively.

Financial Highlights

debt To Equity
0.23
revenue
$0
operating Margin
N/A
total Assets
$518.7M
total Debt
$96.3M
net Income
-$132.4M
eps
N/A
gross Margin
N/A
cash Position
$293.7M
revenue Growth
-100.0%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration revenue$0-100.0%

Key Numbers

  • $132.4M — Net Loss (for the nine months ended September 30, 2025, up from $117.5M in 2024)
  • $293.7M — Cash and Cash Equivalents (as of September 30, 2025, up from $189.8M at December 31, 2024)
  • $376.9M — Proceeds from Underwritten Public Offering (net of issuance costs, for the nine months ended September 30, 2025)
  • $45.0M — Acquired In-Process R&D (for the three months ended September 30, 2025, up from zero in 2024)
  • $84.9M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $25.0M in 2024)
  • $743.7M — Accumulated Deficit (as of September 30, 2025, indicating continued unprofitability)
  • 76.1% — Protection Rate for CD388 (450mg dose) (from symptomatic influenza over 24 weeks in the NAVIGATE study)
  • 31,439,371 — Common Stock Shares Outstanding (as of November 3, 2025)

Key Players & Entities

  • Cidara Therapeutics, Inc. (company) — registrant
  • Janssen Pharmaceuticals, Inc. (company) — previous partner for CD388
  • Napp Pharmaceutical Group Limited (company) — purchaser of rezafungin assets
  • CD388 (product) — lead Cloudbreak product candidate
  • REZZAYO (product) — commercially approved product (rezafungin for injection)
  • Cloudbreak platform (technology) — proprietary drug-Fc conjugate development platform
  • SEC (regulator) — filing oversight
  • Nasdaq Stock Market LLC (company) — exchange where common stock is registered

FAQ

What were Cidara Therapeutics' revenues for the nine months ended September 30, 2025?

Cidara Therapeutics reported no collaboration revenue for the nine months ended September 30, 2025, a decrease from $1.275 million in the same period of 2024.

How much cash and cash equivalents did Cidara Therapeutics have as of September 30, 2025?

As of September 30, 2025, Cidara Therapeutics had $293.651 million in cash and cash equivalents, a significant increase from $189.825 million at December 31, 2024.

What was Cidara Therapeutics' net loss for the three months ended September 30, 2025?

Cidara Therapeutics reported a net loss of $83.233 million for the three months ended September 30, 2025, compared to a net loss of $15.985 million for the same period in 2024.

What is CD388 and what is its current development status at Cidara Therapeutics?

CD388 is Cidara Therapeutics' most advanced Cloudbreak product candidate, an antiviral for influenza. It has completed two Phase 1 studies and one Phase 2a study, and a global Phase 3 trial (ANCHOR study) was initiated in September 2025.

What were the key results of the NAVIGATE study for Cidara Therapeutics' CD388?

The NAVIGATE study for CD388 met its primary and all secondary efficacy endpoints, with single doses of 450mg, 300mg, and 150mg conferring 76.1%, 61.3%, and 57.7% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo.

Why did Cidara Therapeutics' research and development expenses increase significantly?

Research and development expenses increased to $84.946 million for the nine months ended September 30, 2025, from $25.005 million in 2024, largely due to $45.0 million in acquired in-process research and development in Q3 2025 and increased Cloudbreak platform R&D.

What was the impact of the rezafungin asset sale on Cidara Therapeutics' financial statements?

The sale of rezafungin assets to Napp Pharmaceutical Group Limited on April 24, 2024, was classified as discontinued operations. This resulted in no assets or liabilities related to discontinued operations as of September 30, 2025, and a loss from discontinued operations of $450 thousand for the three months ended September 30, 2024.

What is Cidara Therapeutics' accumulated deficit as of September 30, 2025?

As of September 30, 2025, Cidara Therapeutics had an accumulated deficit of $743.689 million, indicating a history of net losses since its inception.

What financing activities did Cidara Therapeutics undertake in the nine months ended September 30, 2025?

Cidara Therapeutics raised $376.910 million from an underwritten public offering and $4.121 million from an at-the-market offering of common stock, net of issuance costs, during the nine months ended September 30, 2025.

What is the primary risk factor for Cidara Therapeutics' future profitability?

The primary risk factor is the successful development and commercialization of its lead product candidate, CD388. The company has a limited operating history, an accumulated deficit of $743.7 million, and expects to continue incurring net losses, making its profitability highly dependent on CD388's success.

Risk Factors

  • Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $743.7 million as of September 30, 2025. This substantial deficit indicates a history of unprofitability and raises concerns about the company's long-term financial sustainability and ability to achieve profitability.
  • Dependence on CD388 Development [high — operational]: Cidara's future success is heavily reliant on the successful development and commercialization of CD388. The company has reacquired all rights for CD388 and initiated a global Phase 3 trial (ANCHOR study) in September 2025. Any setbacks in this trial or regulatory approval process pose a significant risk.
  • Increased R&D and IPR&D Expenses [medium — financial]: Research and development expenses surged to $84.9 million for the nine months ended September 30, 2025, from $25.0 million in 2024. Acquired in-process R&D expenses were $45.0 million for the three months ended September 30, 2025, compared to zero in the prior year. These increased costs contribute to the growing net loss.
  • Discontinued Operations [medium — operational]: The sale of rezafungin assets to Napp Pharmaceutical Group Limited on April 24, 2024, resulted in these assets being classified as discontinued operations. This divestiture impacts the company's revenue streams and strategic focus.
  • Reliance on Public Offerings for Funding [medium — financial]: The company raised $376.9 million from an underwritten public offering. While this significantly boosted cash reserves to $293.7 million, it highlights the company's reliance on external financing to fund its operations and development activities, which may not be sustainable long-term.
  • Clinical Trial Success and Regulatory Approval [high — regulatory]: The initiation of the global Phase 3 ANCHOR study for CD388 is a critical step. The company faces the inherent risks associated with clinical trials, including potential failure to demonstrate efficacy or safety, which could prevent regulatory approval and commercialization.

Industry Context

The biotechnology sector continues to be characterized by high R&D investment and significant regulatory hurdles. Companies like Cidara often rely on strategic partnerships and substantial capital raises to fund the lengthy and expensive drug development process. The focus on novel therapeutics, particularly in areas like infectious diseases, remains a key trend, but success is contingent on demonstrating clinical efficacy and safety.

Regulatory Implications

Cidara's primary regulatory focus is the successful completion of the Phase 3 ANCHOR study for CD388 and subsequent FDA approval. Any delays, adverse findings, or failure to meet endpoints in this critical trial could significantly impact the company's future. The reacquisition of rights and initiation of a global trial suggest a commitment to navigating complex international regulatory pathways.

What Investors Should Do

  1. Monitor the progress and results of the CD388 Phase 3 ANCHOR study.
  2. Assess the company's cash burn rate and future financing needs.
  3. Evaluate the strategic rationale and execution of the CD388 reacquisition and rezafungin divestiture.

Key Dates

  • 2024-04-23: Reacquisition of all rights for CD388 from Janssen. — This strategic move consolidated control over a key development asset, allowing Cidara to drive its future development independently.
  • 2024-04-24: Sale of rezafungin assets to Napp Pharmaceutical Group Limited. — This divestiture allowed Cidara to focus resources on other programs and classified rezafungin as discontinued operations.
  • 2025-09-30: End of the nine-month period for reporting. — Key financial and operational metrics for the period are reported, showing increased net loss and R&D expenses, but also a significantly stronger cash position due to a public offering.
  • 2025-09-30: Initiation of global Phase 3 trial (ANCHOR study) for CD388. — Marks a critical advancement in the development of CD388, moving it into late-stage clinical testing, which is essential for potential regulatory approval.
  • 2025-11-03: Common stock shares outstanding reported. — Indicates the current equity structure of the company, with 31,439,371 shares outstanding.

Glossary

Acquired in-process research and development (IPR&D)
Costs incurred for research and development projects that have not yet reached technological feasibility and have no alternative future use. These are often expensed immediately upon acquisition. (A significant increase in IPR&D expenses to $45.0 million in Q3 2025 heavily impacted the net loss, indicating substantial investment in new R&D assets.)
Accumulated deficit
The cumulative net losses of a company since its inception, less any cumulative net income. It represents the total loss that has not been offset by profits. (The company's accumulated deficit grew to $743.7 million, underscoring its ongoing unprofitability and need for continued funding.)
Discontinued operations
A component of a business that the reporting entity has disposed of or classified as held for sale, and that represents a separate major line of business or geographical area of operations. (The rezafungin assets were classified as discontinued operations following their sale, impacting the company's reported revenue and financial structure.)
Underwritten public offering
A type of public offering where an underwriter (typically an investment bank) buys the securities from the issuer and resells them to the public, assuming the risk of distribution. (Cidara raised $376.9 million through such an offering, significantly bolstering its cash position and providing capital for operations and development.)
Collaboration revenue
Revenue generated from agreements with other companies, often involving joint development, licensing, or marketing of products. (Collaboration revenue was $0 for the nine months ended September 30, 2025, down from $1.3 million in the prior year, reflecting the impact of asset sales.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Cidara Therapeutics reported a significant increase in net loss, driven by a substantial rise in R&D and acquired IPR&D expenses, with total revenues dropping to zero from $1.3 million due to asset divestitures. While total assets more than doubled to $518.7 million, largely due to a successful public offering that increased cash reserves to $293.7 million, the company's accumulated deficit also widened, underscoring its continued unprofitability. New risks related to the advancement of CD388 into Phase 3 trials are now paramount.

Filing Stats: 4,826 words · 19 min read · ~16 pages · Grade level 17.7 · Accepted 2025-11-06 16:25:59

Key Financial Figures

  • $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share CDTX The Nasdaq Stock Market

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders ' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 44

Controls and Procedures

Item 4. Controls and Procedures 45

OTHER INFORMATION

PART II. OTHER INFORMATION 46

Legal Proceedings

Item 1. Legal Proceedings 46

Risk Factors

Item 1A. Risk Factors 46

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 81

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 81

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 81

Other Information

Item 5. Other Information 81

Exhibits

Item 6. Exhibits 82

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) CIDARA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) September 30, 2025 December 31, 2024 (In thousands, except share and per share data) ASSETS Current assets: Cash and cash equivalents $ 293,651 $ 189,825 Restricted cash 6,337 6,352 Short-term investments, available-for-sale 126,370 — Accounts receivable 1,861 1,694 Prepaid expenses and other current assets 14,602 12,866 Total current assets 442,821 210,737 Property and equipment, net 293 521 Finance lease right-of-use asset, net — 703 Operating lease right-of-use asset 1,795 2,739 Long-term investments, available-for-sale 50,159 — Other assets 23,582 96 Total assets $ 518,650 $ 214,796 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,351 $ 3,608 Accrued liabilities 71,349 13,348 Accrued indirect tax liabilities 15,073 26,045 Accrued compensation and benefits 3,506 4,911 Current portion of finance lease liability — 264 Current portion of operating lease liability 1,560 1,378 Total current liabilities 95,839 49,554 Long-term finance lease liability — 310 Long-term operating lease liability 424 1,624 Total liabilities 96,263 51,488 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024: Series A Convertible Voting Preferred Stock, $ 0.0001 par value; 119,912 shares designated at September 30, 2025 and 204,725 shares designated at December 31, 2024; 240,000 shares issued and 119,912 shares outstanding at September 30, 2025 and 240,000 shares issued and 204,725 shares outstanding at December 31, 2024 — — Series X Convertible Preferred Stock, $ 0.0001 par value; 2,843,287 shares designated at September 30, 2025 and 4,947,759 shares designated at December 31, 2024; 2,156,713 shares issued and 0 shares outstanding at September 30, 2025; 2,156,713

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.